 GREENFIELD, Ind.--BUSINESS WIRE--Elanco Animal Health Incorporated NYSE: ELAN today announced it has closed the acquisition of Kindred Biosciences. The transaction advances Elancos access to the fast-growing 1 billion dermatology market, complementing the companys existing pipeline and increasing RD capability in biologics and monoclonal antibodies. The acquisition brings three potential dermatology blockbusters expected to launch through 2025, as well as additional RD program 